2016 SABCS: Clinical Insights for Breast Cancer Treatment

Chapter 1

In this video, Melinda L. Telli, MD, a medical oncologist at Stanford University in Palo Alto, California, discusses the research most likely to have a clinical impact presented at the 2016 San Antonio Breast Cancer Symposium (SABCS). Highlights include ways to reduce the risk of relapse among patients with ER-positive, HER2-negative early breast cancers.

Chapter 2

Frontline Treatments for Patients With Metastatic Breast Cancer

In this video, Melinda L. Telli, MD, a medical oncologist at Stanford University in Palo Alto, California, discusses the frontline treatment of patients with metastatic breast cancer. One important phase 3 trial presented at 2016 SABCS tested the efficacy of fulvestrant against that anastrozole among patients with advanced ER-positive, HER2-negative metastatic breast cancer, though other treatment options are emerging.

Chapter 3

ER-positive, HER2-negative Breast Cancer: A Changing Landscape

In this video, Melinda L. Telli, MD, a medical oncologist at Stanford University in Palo Alto, California, discusses how treatment is changing for patients with ER-positive, HER2-negative disease. Dr Telli notes different factors to consider before choosing a treatment combination for a specific patient, especially for patients whose disease is deemed to be high-risk.

Chapter 4

Triple-negative Breast Cancer: Clinical Insights

In this video, Melinda L. Telli, MD, a medical oncologist at Stanford University in Palo Alto, California, discusses the treatment of patients with triple-negative breast cancer. While there are no fully U.S. Food and Drug Administration (FDA)-approved targeted therapies in this disease setting, there is a great deal of emerging research in this area.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs